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ABSTRACT

This invention relates to a chemical compound that inhibits
the apoptotic activity of the protease Omi/HtrA2 and
homologous proteins. This protease Omi/HtrA2 is present in
all mammalian cells so that inhibition of apoptosis in this
fashion results enhanced cellular health and therapeutic
effects.
4 Claims, No Drawings
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METHOD AND COMPOUND FOR
INHIBITION OF CELL DEATH

cades, in which caspases activate themselves and each other.
Within these cascades, caspases can be positioned as downstream effectors of apoptosis.
U.S. Pat. No. 6,004,794 discloses isolated nucleic acids
encoding a human serine protease PSPI, protein obtainable
from the nucleic acids, recombinant host cells transformed
with the nucleic acids, oligonucleotides and primer pairs
specific for PSPl polymorphisms and use of the protein and
nucleic acid sequences. This patent thus discloses the Omi/
HtrA2 which has been identified as a mitochondrial apoptotic serine protease that also disrupts the inhibition of
apoptosis protein-caspase interaction.
Since the Omi/HtrA2 is present in all mammalian cells
and by its activity of disrupting the inhibition of the "apoptosis protein-caspase interaction" decreases the cell lifetime, it would be most important to discover an inhibitor of
the adverse activity ofOmi/HtrA2 and homologous proteins.

This invention relates to a protease and more particular to
a chemical compound that inhibits the apoptotic activity of
the protease Omi/HtrA2, and method for using such compound for therapeutic use.
BACKGROUND AND PRIOR ART
10

Many of today's medical diseases can be attributed
directly or indirectly to problems with apoptosis-a programmed cell-suicide mechanism. Disorders in which defective regulation of apoptosis contributes to disease pathogenesis or progression can involve either cell accumulation, in
which cell eradication or cell turnover is impaired, or cell
loss, in which the cell-suicide program is inappropriately
triggered. Identification of the genes and gene products that
are responsible for apoptosis, together with emerging information about the mechanisms of action and structures of
apoptotic regulatory and effector proteins, has laid a foundation for the discovery of drugs, some of which are now
undergoing evaluation in human clinical trials.
Typically, one thinks of cell death as being a pathological
phenomenon, but in fact, each second nearly one million
cells commit suicide in the adult human body. In an average
day, we produce, and in parallel eradicate, -60xl0 9 cells
which represents a mass of cells equivalent to an entire body
weight on an annual basis. This massive flux of cell birth and
death occurs in the self-renewing tissues of the body (skin,
gut, bone marrow and sex organs), providing mechanisms
for rapidly regulating cell numbers by controlling the rates
of both input and elimination. Physiological cell death has
important roles in a wide variety of normal processes,
ranging from fetal development to ageing, and including:
immune system education, for which potentially autoreactive cells are eliminated; defense against viruses, for which
altruistic cell suicide can deny viral replication within a host;
tissue homeostasis, for which cell production is offset by
commensurate cell eradication, thereby ensuring appropriate
total cell numbers in vivo; and many aspects ofreproductive
biology.
Programmed cell death is vital to the existence of virtually
all organisms, As a result, knowledge about programmed
cell-suicide mechanisms can have broad ramifications for
devising strategies for protecting crops, interfering with
insect and parasite life cycles, tissue engineering and ex vivo
cell production, and the development of human therapeutics.
Physiological or programmed cell death generally occurs by
apoptosis and defects in the physiological pathways for
apoptosis have a role in many diseases. A reasonable estimate is that either too little or too much cell death contributes to half of the main medical illnesses for which adequate
therapy or prevention is lacking. Consequently, great interest
has emerged in devising therapeutic strategies for modulating the key molecules that make life-or-death decisions in
cells.
Apoptosis is generally caused by proteases known as
"caspases". Caspases constitute a family of intracellular
cysteine proteases that cleave substrates at aspartic acid
(Asp) residues. Produced initially as inactive zygomens,
caspases are triggered into action generally as a result of
their proteolytic processing at conserved Asp residues.
Because caspases both cleave their substrates at Asp residues and are also activated by proteolytic processing at Asp
residues, these proteases can collaborate in proteolytic cas-
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SUMMARY OF THE INVENTION
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The first objective of the present invention is to discover
one or more inhibitors of Omi/HtrA2.
The second objective of the invention is to identify an
inhibitor of Omi/HtrA2 which reduces the inhibition of the
cellular apoptosis protein-caspase interaction.
The third objective of the invention is to discover an
inhibitor of L56 protein.
The fourth objective of the invention is to discover an
inhibitor of bacterial HtrA.
The fifth objective of the invention is to provide a method
for screening for compounds which inhibit apoptosis.
The sixth objective of the invention is to provide a method
for screening for compounds which inhibit Omi/HtrA2.
The preferred embodiments of invention identifies a
chemical inhibitor of Omi/HtrA2 whose structure is

0

//

o--N+

45

50

and its use in the inhibition of excessive mammalian
apoptosis.
Further objects and advantages of this invention will be
apparent from the following detailed description of the
presently preferred embodiments.
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DESCRIPTION OF THE PREFERRED
EMBODIMENT
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Before explaining the disclosed embodiment of the
present invention in detail, it is to be understood that the
invention is not limited in its application to the details of the
particular arrangement shown since the invention is capable
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
It would be useful to discuss the meanings of some words
used herein and their applications before discussing the
novel compound of the invention and its inhibition activity:
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apoptosis-an active process of programmed cell death
characterized by distinct morphological changes in the cell

allograft rejection and graft versus host disease;
type 1 diabetes; and,

caspases-a family of intracellular cysteine proteases that
generally are responsible for apoptosis;

trauma (spinal-cord injury, brain injury).

inhibitor of apoptosis protein (IAP)-contains at least one
copy of Baculovirus IAP of a repeat (BIR) domain and
suppresses apoptosis when overexpressed and is known to
bind and inhibit caspases;
zymogen-the inactive proform of an enzyme which is
typically activated by proteolysis
The invention as noted from the prior art is concerned
basically with the discovery that the activity of Omi/HtrA2
and homologous proteins are inhibited by a compound of the
structure
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EXAMPLE 1
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This structure, whose chemical name is 5-{ 5-(2-nitro-pheny1)-furan-2-y lmethy lene }-1,3-dipheny1-2-thioxo-dihydropyrimidine-4, 6-dione will hereinafter be referred to as UCF
101.
Moreover, Omi/HtrA2 also has homology with other
cellular proteins, such as L56, another mammalian protein,
and bacterial HtrA at the carboxyl terminus of the polypeptides. Thus inhibition of these proteins with UCF 101 is also
indicated. While Om/HtrA2 is sequestered primarily in the
mitochondria, L56 is not and therefore may be even more
susceptible to inhibition. L56 has been shown to be differentially expressed in human osteoarthritic cartilage. Further,
bacteria which lack HtrA are less virulent and thus inhibition
by UCF 101 effectively results in its use as an antibiotic.
By targeting the caspase directly by inhibiting the Omi/
Htr/A2 activity which reduces the inhibition of the cellular
apoptosis protein-caspase interaction, or by virtue of its
serine-protease activity the following applications of the
invention are prospectively useful when excessive apoptosis
in a human is present:
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neuro-degeneration-(Alzheimer's disease, Parkinson's
disease, Hntington's disease and amytrophic lateral sclerosis);
inflammation;

60

osteoarthritis;
human immunodeficiency virus-(loss of T lymphocytes);
bacterial infection-apoptosis-inducing virulence proteins
are secreted into the cytosol of host cell. (Examples are
Shigella spp, Salmonella spp, Yersinia spp and Chlamydia
spp.);

Preparation of FITC-Labeled Unphosphorylated Casein
(FITC-Casein). FITC (Fluorescein Isothiocyanate ), 3 7 .5 mg,
was dissolved in 2.5 ml DMSO. 1.6 ml of this FITC solution
was added with stirring to 800 ml Borate buffer (50 mM
Sodium Borate, pH 9.3, 40 mM NaCl) to make a final
solution of 0.03 mg FITC/ml. 3 ml of casein (2 mg/ml) was
placed in "A Slide-A-Lyzer" Dialysis Cassettes (Pierce, Ill.)
and then placed in freshly prepared labeling solution (Borate
buffer and FITC), covered with aluminum foil and left at 4 °
C. for 2 days with continuous stirring. After labeling, the "A
Slide-A-Lyzer" cassette was placed in dialysis buffer (50
mM Tris-HCl, pH7.5 and 50 mM NaCl) for four days at 40
C with stirring to remove uncoupled FITC. After this time
the casein-FITC conjugate was removed and stored at -20°
C. in the dark.
Protease assay using MBP-Omi 134_458 and FITC-casein.
Opaque microtiter plates were used to minimize background
and assays were always performed in duplicate. In a typical
assay, approximately 10 µg (50 µl) FITC-casein solution was
placed in each well of a microtiter plate well using Multidrop 384 multiple dispenser (Labsystems), and incubated in
the Wallac 1420 Victor2 Multilabel Counter at 37° C. for 15
minutes. After this time 50 µl (2 µg) of MBP-Omi 134_458 in
100 µl of assay buffer (20 mM Sodium Phosphate, pH7.5,
200 mM NaCl, 5% Glycerol) were added. After one minute
delay, the fluorescence change was read every 5 minutes
during 30 minutes at 535 nm. The relative rate for each
reaction was calculated using the fluorescence change in the
initial 20 minutes after subtracting the blank values (no
MBP-Omi134-4ss)Synthesis and purification of MBP-Omi 134_458 .
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ischemia-reperfusion injury (stroke, myocardial infarction).
In addition to apoptotic cell death, necrosis is also present;
heart failure-(loss of myocardiocytes);

Omi shows proteolytic activity in the following assay that
uses ~-casein as a generic substrate. 528 compounds were
screened for inhibition of this assay, and the sole compound
which resulted in inhibited activity was UCF 101:

65

pMAL-c2 prokaryotic expression vector (New England
Biolabs) was used to express f MBP-Omi 134_458 . DNA
primers were designed to PCR amplify the DNA sequence
corresponding to amino acids 134 to 458. The PCR fragment
was cloned into pMAL-c2 to express the Omi 134_458 as a
fusion with MBP. The recombinant protease was purified on
a Maltose-binding affinity column following a standard
protocol (NEB). The concentration of fusion protein was
determined using the Bradford assay. Integrity and purity of
the protein was assessed by SDS-PAGE.
Combinatorial library screening. Six plates of Pharma
Library Collection (Nanosyn, Inc, Calif.) representing a total
of 528 compounds were screened for inhibition of the
proteolytic activity ofMBP-Omi 134_458 . 58 µl ofDMSO was
added to each well containing 30 nmole of a compound (2
µl) to make 500 µM final solution. 2 µl of each of the
compounds was added per well in a microtiter plate followed by 50 µl of a FITC-casein solution (10 ug); after 15
min. preincubation at 370 C, 50 µl of MBP-Omi 134_458 . (2
ug) protease was added. After one minute delay, fluorescence change was monitored every 5 minutes for 30 minutes
at 535 nm.
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EXAMPLE 2

are particularly reserved especially as they fall within the
breadth and scope of the claims here appended.

study using ucf-101 inhibitor to block apoptosis.
Mouse embryo fibroblasts caspase-9-/- were transfected
with pEGFP-Nl as control and M-Omi-GFP, in presence or absence ofucf-101 at increasing concentration
(5 to 25 µM). The percentage of apoptotic cells were
determined using propidium iodide and 4',6'-diamidino-2-phenylindole stains. Normal and apoptotic
GFP-expressing cells were counted using fluorescence
microscopy. Transfected cells treated with inhibitor
ucf-101 showed decreased apoptosis
HeLa cells were transfected with mature Omi (aa134458), Omi-AVPS-GFP and mature Omi where the first
Alanine (A) was mutated to a Glycine. Omi-GVPS-GFP
transfected cells were treated with increasing concentration
ofucf-101. Overexpression of mature Omi-GVPS-GFP can
induce apoptosis only through its ability to function as an
active protease (caspase-independent pathway). Using ucf101 we were able to inhibit its protease activity and apoptosis.
UCF-101 was purchased from Nanosyn (Nonoscale
Cominatorial Synthesis Inc., 625 Clyde Ave, Mountain
View, Calif. 94943-2213
While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope
of the invention is not intended to be, nor should it be
deemed to be, limited thereby and such other modifications
or embodiments as may be suggested by the teachings herein

I claim:
1. A method of inhibiting a protein selected from the
group consisting of Omi/HtrA2, L56, and bacterial HtrA
comprising reacting the protein with a compound of the
formula
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2. A method, as in claim 1, wherein said protein is protein
L56.
3. An method, as in claim 1, wherein said protein is
bacterial HtrA.
4. A method, as in claim 1, wherein said protein is
Omi/HtrA2.
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